Respiratory Syncytial Virus Fusion Protein (RSV F Protein) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Respiratory Syncytial Virus Fusion Protein (RSV F Protein) – Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)

The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects

The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Ablynx NV

Agilvax Inc

Aridis Pharmaceuticals LLC

Aviragen Therapeutics Inc

Bavarian Nordic A/S

Celltrion, Inc.

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Gene Techno Science Co., Ltd.

GenVec, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

iBio, Inc.

Johnson & Johnson

mAbxience S.A.

MedImmune LLC

Medivir AB

Mucosis B.V.

Navigen Pharmaceuticals, Inc.

NeuClone Pty Ltd

Novavax, Inc.

Regeneron Pharmaceuticals Inc

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

The International Biotechnology Center (IBC) Generium

Vaxart Inc

VBI Vaccines Inc

VLP Biotech, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Overview 11

Therapeutics Development 12

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Stage of Development 12

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Therapy Area 13

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Indication 14

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Companies 17

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Universities/Institutes 21

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Companies Involved in Therapeutics Development 29

Ablynx NV 29

Agilvax Inc 30

Aridis Pharmaceuticals LLC 31

Aviragen Therapeutics Inc 32

Bavarian Nordic A/S 33

Celltrion, Inc. 34

Emergent BioSolutions Inc. 35

F. Hoffmann-La Roche Ltd. 36

Gene Techno Science Co., Ltd. 37

GenVec, Inc. 38

Gilead Sciences, Inc. 39

GlaxoSmithKline Plc 40

iBio, Inc. 41

Johnson & Johnson 42

mAbxience S.A. 43

MedImmune LLC 44

Medivir AB 45

Mucosis B.V. 46

Navigen Pharmaceuticals, Inc. 47

NeuClone Pty Ltd 48

Novavax, Inc. 49

Regeneron Pharmaceuticals Inc 50

Takeda Pharmaceutical Company Limited 51

TechnoVax, Inc. 52

The International Biotechnology Center (IBC) Generium 53

Vaxart Inc 54

VBI Vaccines Inc 55

VLP Biotech, Inc. 56

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drug Profiles 57

(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

AK-0529 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ALX-0171 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

AR-201 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

AX-14 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

BTA-585 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

CR-32T - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DT-preF - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

GNR-007 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

GV-2311 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

JNJ-61187165AAA - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

JNJ-61187191AAA - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

JNJ-64400141 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

MEDI-7510 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

MEDI-8897 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MVA-RSV - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

palivizumab biosimilar - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

palivizumab biosimilar - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

palivizumab biosimilar - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

palivizumab biosimilar - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

palivizumab biosimilar - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

palivizumab biosimilar - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

presatovir - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

respiratory syncytial virus (virus like particle) vaccine - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

respiratory syncytial virus (virus like particle) vaccine - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

respiratory syncytial virus (virus like particle) vaccine - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

respiratory syncytial virus (virus like particle) vaccines - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

respiratory syncytial virus immune globulin (human) - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

respiratory syncytial virus vaccine - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

respiratory syncytial virus vaccine - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

respiratory syncytial virus vaccine - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

respiratory syncytial virus vaccine - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

respiratory syncytial virus vaccine - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

respiratory syncytial virus vaccine - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

respiratory syncytial virus vaccine - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

respiratory syncytial virus vaccine - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

RSV-001 - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

RV-521 - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

suptavumab - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

SynGEM - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Dormant Projects 121

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Discontinued Products 122

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Featured News & Press Releases 123

Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus 123

Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 123

Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 124

Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 124

Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults 125

Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126

Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126

Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine 127

Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine 127

Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 128

May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections 129

May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 129

May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 130

May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalized with a RSV infection 131

Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections 132

Appendix 133

Methodology 133

Coverage 133

Secondary Research 133

Primary Research 133

Expert Panel Validation 133

Contact Us 133

Disclaimer 134

List of Tables

List of Tables

Number of Products under Development for, H2 2016 12

Number of Products under Development by Therapy Area, H2 2016 13

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by Ablynx NV, H2 2016 29

Pipeline by Agilvax Inc, H2 2016 30

Pipeline by Aridis Pharmaceuticals LLC, H2 2016 31

Pipeline by Aviragen Therapeutics Inc, H2 2016 32

Pipeline by Bavarian Nordic A/S, H2 2016 33

Pipeline by Celltrion, Inc., H2 2016 34

Pipeline by Emergent BioSolutions Inc., H2 2016 35

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36

Pipeline by Gene Techno Science Co., Ltd., H2 2016 37

Pipeline by GenVec, Inc., H2 2016 38

Pipeline by Gilead Sciences, Inc., H2 2016 39

Pipeline by GlaxoSmithKline Plc, H2 2016 40

Pipeline by iBio, Inc., H2 2016 41

Pipeline by Johnson & Johnson, H2 2016 42

Pipeline by mAbxience S.A., H2 2016 43

Pipeline by MedImmune LLC, H2 2016 44

Pipeline by Medivir AB, H2 2016 45

Pipeline by Mucosis B.V., H2 2016 46

Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 47

Pipeline by NeuClone Pty Ltd, H2 2016 48

Pipeline by Novavax, Inc., H2 2016 49

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 50

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 51

Pipeline by TechnoVax, Inc., H2 2016 52

Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 53

Pipeline by Vaxart Inc, H2 2016 54

Pipeline by VBI Vaccines Inc, H2 2016 55

Pipeline by VLP Biotech, Inc., H2 2016 56

Dormant Projects, H2 2016 121

Discontinued Products, H2 2016 122

List of Figures

List of Figures

Number of Products under Development for, H2 2016 12

Number of Products under Development by Therapy Area, H2 2016 13

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports